Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
November 2, 2022 02:13 PM EDTUpdated 02:48 PM
Pharma

No­vo Nordisk drops two pro­grams as it plots We­govy come­back

Nicole DeFeudis

Editor

Two No­vo Nordisk pro­grams in obe­si­ty and car­dio­vas­cu­lar dis­ease are on the chop­ping block, the com­pa­ny buried in its Q3 re­port, as CEO Lars Fruer­gaard …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times